A prospective, longitudinal study of the renin–angiotensin system, prostacyclin and thromboxane in the first trimester of normal human pregnancy: association with birthweight

Kadi, Hanan Al; Nasrat, Hassan A.; Pipkin, Fiona Broughton

doi:10.1093/humrep/dei184

Cited by 19 publications

(14 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If this occurs, thrombosis, fibrinoid necrosis, and atherosclerosis may be seen in the placenta and decidual vessels and can cause spontaneous abortion, preterm delivery, fetal distress, preeclampsia, and fetal growth restriction [10][11][12][13][14]. Studies of fetal growth restriction and preeclampsia performed with blood samples have reported an increase in TXB2 levels [15][16][17][18][19]. However, others believe that TXB2 does not change much during pregnancy [20].…”

Section: Discussionmentioning

confidence: 99%

Coagulation and prothrombotic state parameters: a clinical analysis during early pregnancy

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Coagulation and prothrombotic state parameters: a clinical analysis during early pregnancy

et al. 2011

View full text Add to dashboard Cite

show abstract

“…During the early stages of normal pregnancy, activation of the local RAS (31,32) and systemic RAS (33,34) exists. At 3-6 gestational weeks, plasma prorenin levels increase 10-fold, with much lower prorenin levels from 9 weeks onward (31).…”

Section: Pre-eclampsia and The Rasmentioning

confidence: 99%

Obstetric Nephrology

Mathiesen

Ringholm

Feldt‐Rasmussen

et al. 2012

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryThis review highlights factors of importance for the clinical care of pregnant women with pregestational diabetes and microalbuminuria or diabetic nephropathy with particular focus on the role of intensive antihypertensive treatment during pregnancy. Most information in the literature comes from women with type 1 diabetes and diabetic nephropathy, but this is probably also valid for women with type 2 diabetes. Careful counseling of women with diabetic nephropathy before pregnancy with estimation of the risk for the mother and fetus is important. Pregnancy does not result in worsening of kidney function in women with diabetic nephropathy and normal serum creatinine, but pregnancy complications such as pre-eclampsia and preterm delivery are common. Intensive metabolic control before and during pregnancy, low-dose aspirin from 12 gestational weeks onward, and intensive antihypertensive treatment are important. Methyldopa, labetalol, and nifedipine are regarded safe in pregnancy, whereas angiotensin converting enzyme inhibitors, AngII antagonists, or statins should be paused before pregnancy. Case series and pathophysiological studies support the use of a stringent goal for BP and albumin excretion in pregnant women with diabetic nephropathy. Screening for diabetic retinopathy before and during pregnancy is mandatory and laser treatment should be performed if indicated. Pregnancy outcome in women with diabetic nephropathy has improved considerably with a take-home-baby rate of approximately 95%. Further research on the benefits and risks of intensive antihypertensive treatment in this population is needed.

show abstract

“…BP increased by approximately 8.3 mmHg per Ang-N gene copy [11,25]. During human pregnancy, plasma Ang-N levels may increase more than 10-fold [26]. The use of oral estrogens may increase Ang-N levels more than 4-fold and systolic BP up to 15 mm Hg [6,8,9,27].…”

Section: Discussionmentioning

confidence: 99%

“…In terms of physiological usefulness, the activation of the renin-angiotensin system by high plasma Ang-N may be a helpful mechanism to compensate for the increased circulatory demands for instance during pregnancy [26]. In situations with exogenous stimulation of plasma Ang-N levels for example by the use of oral contraceptives, such an activation may instead lead to an unwanted BP increase.…”

Section: Discussionmentioning

confidence: 99%

Blood pressure and renin–angiotensin system resetting in transgenic rats with elevated plasma Val5-angiotensinogen

Bohlender

Bäder²,

Ménard³

et al. 2012

Journal of Hypertension

View full text Add to dashboard Cite

High plasma Ang-N increases plasma and kidney Ang-II levels, and amplifies the plasma and renal Ang-II response to a given change in renal renin secretion. This enzyme-kinetic amplification dominates over the Ang-II mediated feedback reduction of renin secretion. High Ang-N levels thus facilitate hypertension via small increases of Ang II and may influence the effectiveness of renin-angiotensin system inhibitors.

show abstract

A prospective, longitudinal study of the renin–angiotensin system, prostacyclin and thromboxane in the first trimester of normal human pregnancy: association with birthweight

Abstract: Angiotensinogen is known to be rate-limiting in pregnancy. Its association with birthweight may be through effects on early plasma volume expansion and may have implications for intrauterine growth restriction and pre-eclampsia.

Cited by 19 publications

References 39 publications

Coagulation and prothrombotic state parameters: a clinical analysis during early pregnancy

Coagulation and prothrombotic state parameters: a clinical analysis during early pregnancy

Obstetric Nephrology

Blood pressure and renin–angiotensin system resetting in transgenic rats with elevated plasma Val5-angiotensinogen

Contact Info

Product

Resources

About